Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma

Clinical Cancer Research

Volumn 19, Issue 16, 2013, Pages 4488-4498

  Lian, Bin ^a   Si, Lu ^a   Cui, Chuanliang ^a   Chi, Zhihong ^a   Sheng, Xinan ^a   Mao, Lili ^a   Li, Siming ^a   Kong, Yan ^a   Tang, Bixia ^a   Guo, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

'INTRON'; CISPLATIN; RECOMBINANT ALPHA2B INTERFERON; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

AGED; ANEMIA; ANOREXIA; ARTICLE; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE MUTATION; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUCOSA MELANOMA; MUCOSAL MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NRAS GENE; ONCOGENE; ONCOGENE C KIT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REPEATED DRUG DOSE; RISK REDUCTION; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GENOTYPE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883011545     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0739     Document Type: Article

References (44)

1. Gutman M, Inbar M, Chaitchik S, Merhav A, Pausner D, Skoznik Y, et al. Malignant melanoma of the mucous membranes. Eur J Surg Oncol 1992;18:307-12.
2. Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino-and Native-American populations. Semin Cutan Med Surg 2009;28:96-102.
3. Chi Z, Li S, Sheng X, Si L, Cui C, Han M, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 2011;11:85.
4. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84, 836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-78.
5. Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and naso-pharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol 2003;27:594-611.
6. Patel SG, Prasad ML, Escrig M, Singh B, Shaha AR, Kraus DH, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002;24:247-57.
7. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003; 129:864-8.
8. Eggermont AM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol 2007;34:509-15.
9. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16:5-24.
10. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039-51.
11. Agarwala SS, Kirkwood JM. Adjuvant therapy of melanoma. Semin Surg Oncol 1998;14:302-10.
12. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102:493-501.
13. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
14. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
15. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19: 2370-80.
16. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvantinterferon-alpha for high-riskmelanoma providea worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003;29:241-52.
17. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
18. Shah GD, Socci ND, Gold JS, Wolchok JD, Carvajal RD, Panageas KS, et al. Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Ann Oncol 2010;21:1718-22.
19. Daponte A, Ascierto PA, Gravina A, Melucci M, Scala S, Ottaiano A, et al. Temozolomide and cisplatin in avdanced malignant melanoma. Anticancer Res 2005;25:1441-7.
20. An JS, Wu LY, Li N, Li B, Yu GZ, Liu LY. [Clinical analysis of 42 cases of primary malignant melanoma in female genital tract]. Zhonghua Fu Chan Ke Za Zhi 2007; 42: 320-4.
21. Li ZY, Cai JQ, Cui XZ, Shao YF, Jin YB. [Outcome of malignant melanoma in gastrointestinal tract: clinical analysis of 70 cases]. Zhonghua Wai Ke Za Zhi 2008;46:574-6.
22. Yang X, Ren GX, Zhang CP, Zhou GY, Hu YJ, Yang WJ, et al. Neck dissection and post-operative chemotherapy with dimethyl triazeno imidazole carboxamide and cisplatin protocol are useful for oral mucosal melanoma. BMC Cancer 2010;10:623.
23. Yi JH, Yi SY, Lee HR, Lee SI, Lim do H, Kim JH, et al. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous meta-static melanoma: multicenter, retrospective analysis in Asia. Melanoma Res 2011;21:223-7.
24. Rutkowski P, Wozniak A, Dȩbiec-Rychter M, Ka̧kol M, Dziewirski W, Zdzienicki M, et al. Clinical utility of thenew AmericanJoint Committee on Cancer staging system for gastrointestinal stromal tumors: current overallsurvival after primary tumor resection.Cancer 2011;117:4916-24.
25. Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, et al. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon a-2b in high-risk acral melanoma patients. Eur J Cancer 2011;47:1498-503.
26. Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 2009;27:939-44.
27. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011;17:1684-91.
28. Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012;48:94-100.
29. Huang SF, Liao CT, Kan CR, Chen IH. Primary mucosal melanoma of the nasal cavity and paranasal sinuses: 12 years of experience. J Otolaryngol 2007;36:124-9.
30. Belli F, Gallino GF, Lo Vullo S, Mariani L, Poiasina E, Leo E. Melanoma of the anorectal region: the experience of the National Cancer Institute of Milano. Eur J Surg Oncol 2009;35:757-62.
31. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
32. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
33. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9.
34. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34.
35. Del Vecchio M, Simeone E, Chiarion Sileni V, Nuzzo C, Rinaldi G, Testori A, et al. Efficacy and safety of ipilimumab in patients with pretreated, mucosal melanoma: experience from Italian clinics participating in the European Expanded Access Programme (EAP) [abstract]. In: Proceedings of the 37th ESMO Congress; 2012 Sep 28-Oct 2; Vienna, Austria. 2012. p. 1130P. Abstract nr 2817.
36. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54:131-49.
37. Bello DM, Smyth E, Perez D, Khan S, Temple LK, Ariyan CE, et al. Anal versus rectal melanoma: does site of origin predict outcome? Dis Colon Rectum 2013;56:150-7.
38. Smyth EC, Flavin M, Barbi A, Bogdatch K, Wolchok JD, Chapman PB, et al. 9330 POSTER Memorial Sloan-Kettering Cancer Center (MSKCC) Single-Institutional Vulvovaginal Mucosal Melanoma (WMM) Experience From 1995-2010. Eur J Cancer 2011;47:S661.
39. Piccioni D, D'Atri S, Papa G, Caravita T, Franchi A, Bonmassar E, et al. Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 1995;7:224-9.
40. Flaherty LE, Moon J, Atkins MB, Tuthill R, Thompson JA, Vetto JT, et al. Phase III trial of high-dose interferon alpha-2b versus cisplatin, vin-blastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG [abstract]. J Clin Oncol 30, 2012 (suppl; abstr 8504).
41. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
42. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6.
43. Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2005;16:950-7.
44. Wierzbicka-Hainaut E, Sassolas B, Mourey L, Guillot B, Bedane C, Guillet G, et al. Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial. Melanoma Res 2010;20:141-6.